TheraVitae Inc. Files Lawsuit Against RegenoCELL Therapeutics, Inc.
The lawsuit claims damages against RegenoCELL in the amount of $3,000,000, an accounting of all revenues and profits earned by RegenoCELL from its wrongful activities and an injunction requiring RegenoCELL to cease using TVI's intellectual propert
Toronto, Canada (I-Newswire) November 10, 2010 - TheraVitae Inc.(TVI) announced today that it filed a lawsuit on October 6, 2010 against RegenoCELL Therapeutics, Inc.(RegenoCELL), a public US company (PINK: RCLL-Private), for breach of a Confidentiality and Non-Circumvention Agreement (the Agreement) dated April 4, 2008, breach of trust, conversion and trade-mark infringement. The lawsuit was filed in the Ontario Superior Court of Justice.
TVI claims that RegenoCELL has violated the Agreement by engaging in the unauthorized dissemination of confidential information belonging to TVI, including technical data, ideas, designs, inventions and trade secrets, and by using TVI's confidential information and intellectual property -- including TVI's trade-mark -- to compete with and circumvent the efforts of TVI.
The lawsuit claims damages against RegenoCELL in the amount of US $3,000,000, an accounting of all revenues and profits earned by RegenoCELL from its wrongful activities and an injunction requiring RegenoCELL to cease using TVI's intellectual property assets and confidential information and to return same to TVI.
TheraVitae Inc. is an autologous (patient's own) stem cell therapy company engaged in the research, development, formulation, clinical testing, registration, manufacture and commercialization of heart repair and peripheral arterial disease repair stem cell processing. Our core competency lies in our expertise to derive, propagate and differentiate a synergetic cell population from a patient's peripheral blood into neuronal cell precursors, cardiomyocyte cell precursors, and angiogenic cell precursors. VesCell, our first product, is a synergetic cell population of angiogenic cell precursors. It is used by physicians to treat end-stage heart failure and peripheral arterial disease ("PAD") on a compassionate care basis. VesCell has been used in the treatment of more than 500 patients.
- 30 -
David M. Reese
49 Front Street East, Suite 400
Phone : 647-288-7123
Published On:November 10, 2010
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
Caltron Introduces A New Really Small Form Factor Monitor To The Line Of Open Frame Monitors
Christie Takes Simulation Display Solutions on the Road to Orlando April 30 and May 1
Grow Your Business With OSCommerce Development
Encoding.com Launches Support for MPEG-DASH
B-Scada Announces the Shipping Release of Status Enterprise